Latest Breaking News On - Professor shun - Page 1 : comparemela.com

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

SHANGHAI, China, Jan. 02, 2024 Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of.

United kingdomSan franciscoUnited statesJunshi biosciencesZhi liShanghai junshi biosciences co ltdWorld health organizationDrug administrationPr teamNational reimbursement drug listAmerican society of clinical oncologyAustralia therapeutic goods administrationNational medical products administrationIr teamRegulatory agencyEuropean medicines agency

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof Shun Lu to its Clinical Advisory Board

/PRNewswire/ Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today.

United statesOpdivo nivolumabRita laeufleTechnology progressTechnology awardPhanes therapeutics incBoard member of anticancer associationShanghai jiao tong universityAmerican clinical oncology societyTel aviv universityCommittee memberShanghai jiao tong university chest hospitalMd anderson cancer centerInternational affairs committeePrnewswire phanes therapeutics incTechnology award of china association

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSan franciscoZhi liJunshi bioscienceJunshi biosciencesDrug administrationGlobal researchNational reimbursement drug listNational medical products administrationIr teamWorld health organizationData monitoring committeeRegulatory agencyPr teamEuropean medicines agency

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

United statesUnited kingdomSan franciscoZhi liJunshi bioscienceJunshi biosciencesRegulatory agencyGlobal researchNational reimbursement drug listData monitoring committeeDrug administrationPr teamIr teamWorld health organizationEuropean medicines agencyNational medical products administration

Junshi Biosciences Announces Toripalimab as Perioperative

SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading.

United statesUnited kingdomSan franciscoJunshi bioscienceJunshi biosciencesZhi liIr teamWorld health organizationDrug administrationData monitoring committeeRegulatory agencyBlind independent pathology review committeeNational reimbursement drug listEuropean medicines agencyPr teamInstitute of microbiology the chinese academy